Participants 58 110 6
patients with relapsing-remitting multiple sclerosis
Participants 277 392 4
patients with relapsing-remitting multiple sclerosis was well tolerated and reduced the formation of active lesions
Participants 584 612 5
51 centres in nine countries
Participants 779 800 16
306 eligible patients
